Questions with the most recent answer or edit.
Conditions: Wuxi · Poland. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree, which is…
I have been reading across the programmes and the A1c numbers do not line up in any way I can make sense of. SURPASS-2 reports tirzepatide lowering A1c by more than 2…
Stated plainly: cystatin C · survodutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan with explicit stopping…
The specifics, since they change the answer: oral semaglutide · minus 20 °C. Somebody stated this to me confidently and I would like to check it before repeating it.…
What I am working with: aggregation · 30 °C. I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious. My background…
I have both a purity figure and a content figure, which is why the discrepancy is visible. I would like to define my thresholds before I have a result, for obvious…
Stated plainly: PeptideMeter · Qingdao Saber Technology. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern…
Setup, so nobody has to ask: GGT · four weeks · retatrutide. I think I have a problem. I am not yet sure whether it is a real problem or a measurement artefact. I…
I would like to know what to measure as much as what to do. These are treated as interchangeable and I do not think they are. If both are acceptable I would like to…
Details up front: WXT · Xi’an Mokemei Biotechnology. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain…
The specifics, since they change the answer: HJ · QYB · Ireland. I would like the axes of comparison first and the recommendation second. I have tried the first…
The case in front of me: PeptideMeter · Hunan Aslsen Technology. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I…
The case in front of me: PeptideMeter · 98.2%. I have two candidate explanations and no way to distinguish them. The same procedure has worked without incident…
The case in front of me: a 27G needle · tirzepatide · 4 mg/mL. I would like the axes of comparison first and the recommendation second. I have tried the first option…
For reference: 96.4% · a wide-pore C18 column · a GLP-1 receptor agonist. I want to understand what this actually establishes, as opposed to what it is being used to…
Numbers first: a 29G needle · retatrutide · 3.33 mg/mL. I have used one of these for a while and I am considering switching, which requires a reason. What I care…
Conditions: 1 mg · four weeks · early satiety. This is one of those things that everyone repeats and nobody derives. This matters practically, not just academically,…
I am reading the trial table rather than the press release, which is why the numbers differ. I want to understand what this actually establishes, as opposed to what…
The case in front of me: STEP 2 · 1 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
Stated plainly: 96.8% · batch certificate. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…
The case in front of me: ecnoglutide · 20 mg/mL · ten weeks. The claim is plausible, which is exactly why I want to check it. I am able to read a paper if someone…
I am comparing a supplier certificate against an independent result on the same lot. I keep seeing this stated as a fact with no explanation attached, and unexplained…
The lane and the lead time matter as much as the material for what I am doing. I can parse the result. I am less sure what it licenses me to conclude. I have…
What I am working with: retatrutide · mazdutide. Both of these get recommended confidently by different people, which suggests neither is obviously right. My…